# Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)

> **NCT00633139** · PHASE1,PHASE2 · COMPLETED · sponsor: **Shire** · enrollment: 13 (actual)

## Conditions studied

- Late Infantile Metachromatic Leukodystrophy

## Interventions

- **BIOLOGICAL:** Recombinant human Arylsulfatase A (rhASA)

## Key facts

- **NCT ID:** NCT00633139
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01-22
- **Primary completion:** 2008-11-25
- **Final completion:** 2008-11-25
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2021-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00633139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00633139, "Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00633139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*